Translate
Text Highlighter

Bookmark

PDF

Share

Report a problem

RACHAEL SHAY, indi v. dually and on behalf of all others similarly situated, Plaintiff,

Hon. Gonzalo P. Curiel United States District Judge

ORDER GRANTING DEFENDANTS' PARTIAL MOTION TO DISMISS THE SECOND AMENDED COMPLAINT WITHOUT LEAVE TO AMEND [DKT. NO. 21.]

Before the Court is Defendants' partial motion to dismiss the second amended complaint. (Dkt. No. 21.) Plaintiff filed an opposition and Defendants replied. (Dkt. Nos. 23, 24.) Based on the reasoning below, the Court GRANTS Defendants' partial motion to dismiss the second amended complaint without leave to amend.

Background

This case was removed from state court on August 21, 2020. (Dkt. No. 1.) On January 8, 2021, the Court granted in part and denied in part Defendants' motion to dismiss the first amended complaint with leave to amend. (Dkt. No. 17.) On January 28, 2021, Plaintiff Rachael Shay ("Plaintiff") filed the operative putative second amended class action complaint ("SAC") against Defendants Apple, Inc. and Apple Value Services, LLC ("Defendants" or "Apple") for claims under the 1) California Legal Remedies Act, ("CLRA"), California Civil Code §1750 et seq.; 2) violations of the Unfair Competition Law ("UCL"), California Business &Professions Code section 17200 et. seq.; 3) negligent misrepresentation; and 4) breach of the implied warranty of merchantability. (Dkt. No. 18, SAC ¶¶ 41-88.)

The SAC alleges that Defendants manufactured, marketed, sold and/or distributed valueless Apple gift cards that they knew or should have known was subject to an "ongoing scam where the funds on the gift cards are fraudulently redeemed by third parties accessing the Personal Identification Number ("PIN") prior to use by the consumer." (Id., SAC ¶ 2.) On April 3, 2020, Plaintiff purchased a $50 Apple gift card from Walmart in Encinitas, CA as a gift for her son. (Id. ¶ 10.) When her son attempted to load the gift card, he received a message that the gift card had already been redeemed. (Id.) Plaintiff contacted Defendants and was informed that the gift card was redeemed by another account on April 3, 2020, the same day she bought the card, and the card no longer had any value. (Id.) Defendants would not provide any additional information about who redeemed the code, other than it was an account unrelated to Plaintiff or her son. (Id.) Defendants informed her that there was nothing they could do for her, that her case was closed, and any further contact would go unanswered. (Id.) If Plaintiff had known about the truth about the defect of Defendants' gift card, she would not have purchased it. (Id.)

Plaintiff seeks to bring this class action on behalf of the following:

Nationwide Class:
All consumers in the United States who purchased an Apple gift card wherein the funds on the Apple gift card was (sic) redeemed prior to use by the consumer. Excluded from this Class are Defendants and their officers, directors and employees, and those who purchased Apple gift cards for the purpose of resale.

California Subclass:
All consumers in the State of California who purchased an Apple gift card wherein the funds on the Apple gift card was (sic) redeemed prior to use by





the consumer. Excluded from this Class are Defendants and their officers, directors and employees, and those who purchased Apple gift cards for the purpose of resale.

(Id. ¶ 32.)

Defendants move to dismiss the UCL claim in its entirety, the CLRA to the extent she seeks equitable relief in addition to or in lieu of damages, and the breach of the implied warranty of merchantability. (Dkt. No. 21.) Plaintiff filed an opposition and Defendants filed a reply. (Dkt. Nos. 23, 24.)

Discussion A. Legal Standard on Federal Rule of Civil Procedure 12(b)(6)

Federal Rule of Civil Procedure ("Rule") 12(b)(6) permits dismissal for "failure to state a claim upon which relief can be granted." Fed. R. Civ. P. 12(b)(6). Dismissal under Rule 12(b)(6) is appropriate where the complaint lacks a cognizable legal theory or sufficient facts to support a cognizable legal theory. See Balistreri v. Pacifica Police Dep't., 901 F.2d 696, 699 (9th Cir. 1990). Under Federal Rule of Civil Procedure 8(a)(2), the plaintiff is required only to set forth a "short and plain statement of the claim showing that the pleader is entitled to relief," and "give the defendant fair notice of what the . . . claim is and the grounds upon which it rests." Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007).

A complaint may survive a motion to dismiss only if, taking all well-pleaded factual allegations as true, it contains enough facts to "state a claim to relief that is plausible on its face." Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Twombly, 550 U.S. at 570). "A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged." Id. "Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice." Id. "In sum, for a complaint to survive a motion to dismiss, the non-conclusory factual content, and reasonable inferencuty under the Federal Food, Drug and Cosmetic Act ("FFDCA"). The panel held that the EPA spent more than a decade assembling a record of chlorpyrifos's ill effects and repeatedly determined, based on that record, that it could not conclude, to the statutorily required standard of reasonable certainty, that the present tolerances caused no harm. Rather than ban the pesticide or reduce the tolerances to levels that the EPA could find were reasonably certain to cause no harm, the EPA sought to evade through delay tactics its plain statutory duty. , 580 F.3d 949, 956 (9th Cir. 2009).

Where a motion to dismiss is granted, "leave to amend should be granted 'unless the court determines that the allegation of other facts consistent with the challenged pleading could not possibly cure the deficiency.'" DeSoto v. Yellow Freight Sys., Inc., 957 F.2d 655, 658 (9th Cir. 1992) (quoting Schreiber Distrib. Co. v. Serv-Well Furniture Co., 806 F.2d 1393, 1401 (9th Cir. 1986)). In other words, where leave to amend would be futile, the Court may deny leave to amend. See DeSoto, 957 F.2d at 658; Schreiber,

B. UCL and CLRA Claims for Failing to Plead Inadequate Remedy at Law

Defendants move to dismiss the UCL claim and the CLRA claim to the extent it seeks equitable relief arguing that Plaintiff has not alleged an inadequate remedy at law relying on Sonner v. Premier Nutrition Corp., 971 F.3d 834 (9th Cir. June 17, 2020). (Dkt. No. 21 at 8-11.) Plaintiff opposes arguing it can seek both actual damages and equitable relief relying on Moore v. Mars Petcare U.S., Inc., 966 F.3d 1007, 1021 n. 13 (9th Cir. July 28, 2020).

Page numbers are based on the CM/ECF pagination.

Under the UCL, a plaintiff may only seek the equitable relief of restitution and/or an injunction. Korea Supply Co. v. Lockheed Martin Corp., 29 Cal. 4th 1134, 1144 (2013) ("Through the UCL a plaintiff may obtain restitution and/or injunctive relief against unfair or unlawful practices."). The CLRA allows for a number of remedies including actual damages, restitution, injunctive relief and punitive damages. See Cal. Civ. Code § 1780.

The SAC seeks restitution and injunctive relief under the CLRA and UCL claims and alleges that "[i]n the event adequate legal remedies are lacking", Plaintiff seeks an injunction and restitution. (Dkt. No. 18, SAC ¶¶ 46, 65.)

In Sonner, the Ninth Circuit, relying on United States Supreme Court precedent, held that "traditional principles governing equitable remedies in federal courts, including the requisite inadequacy of legal remedies, apply when a party requests restitution under the UCL and CLRA in a diversity action." Sonner v. Premier Nutrition Corp., 971 F.3d 834, 844 (9th Cir. 2020). In line with this, the court held that a plaintiff must allege that she "lacks an adequate remedy at law before securing equitable restitution for past harm under the UCL and CLRA." Id. (citations omitted). Pointing out that the operative complaint did not allege that Sonner lacked an adequate legal remedy and the equitable restitution she sought was the same as damages she sought to compensate for the same past harm, the Ninth Circuit affirmed dismissal of the equitable restitution claim under the UCL and CLRA. Sonner, 971 F.3d at 844 (citing O'Shea v. Littleton, 414 U.S. 488, 502 (1974) (holding that a complaint seeking equitable relief failed because it did not plead "the basic requisites of the issuance of equitable relief" including "the inadequacy of remedies at law")).

The SAC alleges CAFA jurisdiction. (Dkt. No. 18, SAC ¶ 6). CAFA vests federal courts with "'original' diversity jurisdiction over class actions." Serrano v. 180 Connect, Inc., 478 F.3d 1018, 1020-21 (9th Cir. 2007). Thus, the reasoning of Sonner applies to this case.

While Sonner's holding was limited to the equitable relief of restitution, Sonner, 971 F.3d at 842 (noting that "injunctive relief [was] not at issue"), district courts have held that the "adequate remedy at law" requirement applies to equitable relief, which includes injunctive relief claims. See Audrey Heredia v. Sunrise Senior Living LLC, Case No. 8:18-cv-01974-JLS-JDE, 2021 WL 819159, at *4 (C.D. Cal. Feb. 10, 2021) (inadequate remedy at law applies to all claims for equitable relief) (citing IntegrityMessageBoards.com v. Facebook, Inc., No. 18-CV-05286-PJH, 2020 WL 6544411, at *5 (N.D. Cal. Nov. 6, 2020) ("Whatever the facts before the panel in Sonner, the Supreme Court in York did not draw any distinction among the various forms of equitable relief when requiring the absence of a 'plain, adequate, and complete remedy at law' to obtain it."); Huynh v. Quora, Inc., No. 5:18-CV-07597-BLF, 2020 WL 7495097, at *19 (N.D. Cal. Dec. 21, 2020) ("Cases in this Circuit have held that Sonner extends to claims for injunctive relief.") (collecting cases); In re MacBook Keyboard Litig., No. 5:18CV2813-EJD, 2020 WL 6047253, at *3 (N.D. Cal. Oct. 13, 2020) ("[N]umerous courts in this circuit have applied Sonner to injunctive relief claims.")).

Guaranty Trust Co. of New York v. York, 326 U.S. 99 (1945). --------

In opposition, Plaintiff argues that the Ninth Circuit's "binding" ruling in Moore applies in this case. (Dkt. No. 23 at 8-12.) In Moore, the Ninth Circuit reversed the district court's dismissal order on the UCL, CLRA and False Advertising Law ("FAL") claims concluding that the plaintiffs adequately alleged these claims under Rule 12(b)(6) and Rule 9(b). Moore, 966 F.3d at 1016-17. In a footnote, the court rejected the defendants' additional argument that the plaintiffs could not seek equitable relief under the UCL or FAL because the CLRA provided an adequate legal remedy. Id. at 1021 n. 13. The court summarily stated that the UCL, FAL and CLRA "explicitly provide that remedies under each act are cumulative to each other." Id. Plaintiff argues that Moore resolved the split of authority in favor of allowing UCL claims to proceed with legal claims.

The Court disagrees. First, the footnote in Moore is dicta and not binding on this Court. Unlike Sonner which provided an analysis on equitable remedies in federal court, Moore makes a summary statement without any analysis or mention of Sonner. Moreover, as one district court noted, the court in Moore only stated that the remedies under the UCL, FAL, and CLRA are "cumulative with one another, not with separate legal remedies." See In re Subaru Battery Drain Prods. Liab. Litig., Civil Action No. 1:20-cv-03095-JHR-JS, 2021 WL 1207791, at *28 (D.N.J. Mar. 31, 2021) ("Plaintiffs cannot seek equitable remedies under the UCL and CLRA that are cumulative to their legal remedies."). In addition, all district courts that have been confronted with the argument that Moore should be the authority courts should follow instead of Sonner have all rejected the significance of the footnote in Moore. See Sharma v. Volkswagen AG, --- F. Supp. 3d ---, 2021 WL 912271, at *8 (N.D. Cal. Mar. 9, 2021) (rejecting plaintiffs' argument on applicability of Moore); In re Subaru Battery Drain Prods. Liab. Litig., 2021 WL 1207791, at *28; Audrey Heredia, 2021 WL 819159, at *3 ("The Court, however, concludes that the clear holding in Sonner, not the dictum in Moore, controls whether Plaintiffs' UCL claim is subject to an "adequate legal remedy" requirement."); IntegrityMessageBoards.com v. Facebook, Inc., 2020 WL 6544411, at *4. Finally, Sonner, and not Moore, actually resolved the split in authority on whether plaintiff must plead an inadequate remedy at law in order to seek equitable relief under the UCL and CLRA. See Anderson v. Apple Inc., --- F. Supp. 3d ---, 2020 WL 6710101, at *7 (N.D. Cal. Nov. 16, 2020) (Sonner appears to have resolved the split in authority). Thus, the Court disagrees with Plaintiff's assertion that Moore's analysis is sound and binding on this Court.

Plaintiff also argues that reliance on Sonner is misplaced due to the procedural posture of the case as the UCL claim along with a legal claim proceeded until the eve of trial. (Dkt. No. 23 at 14-15.) However, district courts have rejected a plaintiff's attempt to distinguish Sonner based on the procedural posture of the case. See Teresa Adams v. Cole Haan, LLC, Case No. Sacv 20-913 JVS (DFMx), 2020 WL 5648605, at *2 (C.D. Cal. Sept. 3, 2020) (procedural posture in Sonner did not affect analysis of the traditional division between law and equity); Zaback v. Kellogg Sales Co., No. 20-00268 BEN MSB, 2020 WL 6381987, at *4 (S.D. Cal. Oct. 29, 2020) (collecting cases that have "applied Sonner to dismiss complaints in cases involving similar claims at the more familiar early stages of litigation"). In fact, in Sonner, the Ninth Circuit pointed out that the operative complaint did not allege that the plaintiff lacked an adequate legal remedy. See Sonner, 971 F.3d at 844. This suggests that a plaintiff must plead inadequate legal remedies in the operative pleading to allege claims for equitable relief under the UCL and CLRA.

Plaintiff further attempts to distinguish Sonner by noting that Judge Seeborg, the district judge in the Sonner case, subsequently issued decisions in Bland v. Sequel Nat. Ltd., No. 18-cv-04767-RS, 2019 WL 4674337 (N.D. Cal. Aug. 2, 2019) and Marshall v. Danone US, Inc., 402 F. Supp. 3d 831 (N.D. Cal. Sept. 13, 2019) that distinguished his own decision in Sonner. The district court in Sharma rejected the same argument noting that Judge Seeborg decided both those cases before the Ninth Circuit's decision in Sonner. Sharma, 2021 WL 912271, at *7. For the same reasons, Plaintiff's reliance on Judge Seeborg's pre-Sonner cases is not supportive.

Finally, Plaintiff argues that under Rule 8, she may seek equitable claims in the alternative. (Dkt. No. 23 at 12-13.) Yet, all the cases she cites pre-date Sonner. On this same argument, the Court agrees with the district court in Sharma stating that "[t]he issue is not whether a pleading may seek distinct forms of relief in the alternative, but rather whether a prayer for equitable relief states a claim if the pleading does not demonstrate the inadequacy of a legal remedy. On that point, Sonner holds that it does not." See Sharma, 2021 WL 912271, at *8. Moreover, Plaintiff's reliance on Moyle v. Liberty Mutual Retirement Benefit Plan, 823 F.3d 948, 962 (9th Cir. 2016), for the proposition that Rule 8 allows "equitable remedies alongside a legal claim that separately 'provides adequate relief"", (Dkt. No. 23 at 13), is distinguishable as Moyle dealt with ERISA which has its own distinct purpose of protecting participants' and beneficiaries' interests. See IntegrityMessageBoards.com, 2020 WL 6544411, at *5 (rejecting the plaintiff's reliance on Moyle to support that argument that equitable remedies may be plead in the alternative). Therefore, Plaintiff's Rule 8 argument is not convincing to the Court.

In sum, the Court concludes that Sonner is binding on this Court and now considers whether Plaintiff has plausibly alleged an inadequate remedy at law. In its prior order, the Court granted Plaintiff leave to amend and explained that Sonner required that Plaintiff must allege she "lacks an adequate legal remedy." (Dkt. No. 17 at 15-16.) In the SAC, Plaintiff solely adds the allegation, "In the event adequate legal remedies are lacking . . . Plaintiff and the class seek a court order enjoining the . . . wrongful acts and practices of Defendants and for restitution and disgorgement. (Dkt. No. 18, SAC ¶ 46; see id. ¶ 65.) A contingent event does not support an allegation that Plaintiff has an inadequate remedy at law. Plaintiff has not demonstrated that this allegation is sufficient to support equitable relief under Sonner. Accordingly, the Court GRANTS Defendants' motion to dismiss the UCL claim and the equitable relief she seeks in the CLRA claim.

C. Breach of Implied Warranty of Merchantability

Defendants move to dismiss the breach of implied warranty claim because Plaintiff has not alleged she is in privity with Apple or that an exception to the privity requirement applies. (Dkt. No. 21-1 at 11-13.) Plaintiff responds that vertical privity is not required because she is a third-party beneficiary who purchased the gift card from a third party acting as an agent for Defendants. (Dkt. No. 23 at 16-18.)

On privity, the SAC now alleges, "Plaintiff and Class Members purchased the Apple gift cards from Apple gift card retailers that are agents of Defendants. However, the retailers were not intended to be the ultimate consumers of the Apple gift cards and have no implied warranty rights. Instead, Plaintiff and Class Members were the intended ultimate consumers of the Apple gift cards. As such, Plaintiff and Class Members assert their implied warranty rights as third party beneficiaries." (Dkt. No. 18, SAC ¶ 84.)

The California Commercial Code "implies a warranty of merchantability that goods '[a]re fit for ordinary purposes for which such goods are used.'" Birdsong v. Apple, Inc., 590 F.3d 955, 958 (9th Cir. 2009) (quoting Cal. Com. Code § 2314(2)(c)). "Under California Commercial Code section 2314, . . . a plaintiff asserting breach of warranty claims must stand in vertical contractual privity with the defendant." Clemens v. DaimlerChrysler Corp., 534 F.3d 1017, 1023 (9th Cir. 2008); All West Elecs., Inc. v. M-B-W, Inc., 64 Cal. App. 4th 717, 725 (1998) ("The general rule is that privity of contract is required in an action for breach of either express or implied warranty and that there is no privity between the original seller and a subsequent purchaser who is in no way a party to the original sale."); Anthony v. Kelsey-Hayes Co., 25 Cal. App. 3d 442, 448 (1972) ("It is settled law in California that privity between the parties is a necessary element to recovery on a breach of an implied warranty of [merchantability or] fitness for the buyer's use, with exceptions not applicable here."). "A buyer and seller stand in privity if they are in adjoining links of the distribution chain." Clemens, 534 F.3d at 1023. An "end consumer" who "buys from a retailer is not in privity with a manufacturer." Id.

In Clemens, the Ninth Circuit identified a number of specific exceptions to the privity rule such as cases when a "plaintiff relies on written labels or advertisements of a manufacturer" and other "special cases involving foodstuffs, pesticides, and pharmaceuticals, and where the end user is an employee of the purchaser." Id. at 1023 (citing Burr v. Sherwin Williams Co., 42 Cal. 2d 682, 695-96 (1954); Windham at Carmel Mountain Ranch Ass'n v. Superior Ct., 109 Cal. App. 4th 1162, 1169 (2003); Fieldstone Co. v. Briggs Plumbing Prods., Inc., 54 Cal. App. 4th 357, 369 (1997); Gottsdanker v. Cutter Labs., 182 Cal. App. 2d 602, 608 (1960)). A direct dealing exception to the privity requirement was also recognized by the court of appeal in U.S. Roofing, Inc. v. Credit Alliance Corp. 228 Cal. App. 3d 1431, 1442 (1991). Cardinal Health 301, Inc. v. Tyco Electronics Corp.,169 Cal. App. 4th 116, 138-39 (2008) (applying direct dealing exception). The Ninth Circuit noted that California "has painstakingly established the scope of the privity requirement under [ ] section 2314, and a federal court sitting in diversity is not free to create new exceptions to it." Clemens, 534 F.3d at 1024.

Before and after the Ninth Circuit ruling in Clemens, district courts in California have been split on whether an exception to the privity requirement exists for a breach of implied warranty of merchantability claim when a plaintiff can show that he or she was a third-party beneficiary of a contract between the defendant and a third party. Compare Zeiger v. WellPet LLC, 304 F. Supp. 3d 837, 854 (N.D. Cal. 2018) (recognizing split in authority but adopting third-party beneficiary exception); In re MyFord Touch Consumer Litig., 46 F. Supp. 3d 936, 984 (N.D. Cal. 2014) ("the Court concludes that the third-party beneficiary exception remains viable under California law."); In re Sony Vaio Computer Notebook Trackpad Litig., No. 09CV2109 BEN (RBB), 2010 WL 4262191, at *3 (S.D. Cal. Oct. 28, 2010) (finding that the plaintiffs had plausibly pleaded that the exception applied when they purchased a Sony laptop from Best Buy, which they alleged was an authorized Sony retailer and service facility); Kearney v. Hyundai Motor Am., No. SACV09-1298-JST MLGX, 2010 WL 8251077, at *10 (C.D. Cal. Dec. 17, 2010) with Skiathitis v. Nyko Techs., Inc., No. 18-3584, 2018 WL 6427360, at *11 (C.D. Cal. Sept. 12, 2018) ("The applicability of the third-party beneficiary exception to retail consumers like Plaintiffs is far from settled, but the Court concludes that the best reading of California law is that the exception does not apply."); Xavier v. Philip Morris USA, Inc., 787 F. Supp. 2d 1075, 1083 (N.D. Cal. 2011) (finding that the exception does not apply because "[n]o reported California decision has held that the purchase of a consumer product may dodge the privity rule by asserting that he or she is a third-party beneficiary of the distribution agreements linking the manufacturer to the retailer who ultimately made the sale"); Anunziato v. eMachines, Inc., 402 F. Supp. 2d 1133, 1141 (C.D. Cal. 2005) (third-party beneficiary exception does not allow a consumer who purchased a laptop from BestBuy.com to bring a breach of implied warranty claim against the laptop manufacturer).

It is notable that "no published decision of a California court has applied this [third party beneficiary exception] doctrine in the context of a consumer claim against a product manufacturer." Loomis v. Slendertone Distrib., Inc., 420 F. Supp. 3d 1046, 1089 (S.D. Cal. 2019) (quoting In re Seagate Tech. LLC Litig., 233 F. Supp. 3d 776, 787 (N.D. Cal. 2017)); see also Xavier v. Philip Morris USA, Inc., 787 F.Supp.2d 1075, 1083 (N.D Cal. 2011) ("No reported California decision has held that the purchaser of a consumer product may dodge the privity rule by asserting that he or she is a third-party beneficiary of the distribution agreements linking the manufacturer to the retailer who ultimately made the sale.")

District courts that have adopted the third-party beneficiary exception theory rely on Gilbert Fin. Corp. v. Steelform Contracting Co., 82 Cal. App. 3d 65, 69-70 (1978). In that case, the court of appeal reversed the trial court's dismissal of the breach of implied warranty claim for lack of privity made against a roofing sub-contractor and held that the plaintiff could bring such action for breach of an implied warranty of fitness against the sub-contractor because he, the owner of a building who was not named in the contract, was the intended third-party beneficiary of the contract between the contractor and the roofing subcontractor. Id. at 69-70. The court of appeal noted that it did not have to decide the privity issue because the plaintiff was a third-party beneficiary of the contract between the contractor and sub-contractor and could therefore sue for breach of the implied warranty of fitness. Id. at 69. Gilbert is specific to its facts and has limited bearing on this case. While courts are split on recognition of the third-party beneficiary exception to the privity requirement, the cases that recognize it require a plaintiff to show that he was a third-party beneficiary of a contract between the defendant and a third party. In re NVIDIA GPU Litig., No. C 08-04312 JW, 2009 WL 4020104, at *7 (N.D. Cal. Nov. 19, 2009) (exception to the privity requirement for a breach of implied warranty of merchantability claim if a plaintiff can show that he was a third party beneficiary of a contract between the defendant and a third party); In re Nexus 6P Prod. Liab. Litig., 293 F. Supp. 3d 888, 924 (N.D. Cal. 2018) ("Huawei concedes that the relevant states allow plaintiffs to bring implied warranty claims in the absence of privity if the plaintiff shows that he was a beneficiary to a contract between the defendant and a third party.")

To the extent that California recognizes a third-party beneficiary exception to the privity requirement, Plaintiff has failed to allege a contract was entered into between Walmart and Apple for Plaintiff's benefit. Instead, Plaintiff merely alleges that the Apple gift card retailers "are agents of Defendants" and that "the retailers were not intended to be the ultimate consumers of the Apple gift cards and have no implied warranty rights. Instead, Plaintiff and Class Members were the intended ultimate consumers of the Apple gift cards." (Dkt. No. 18, SAC ¶ 84.) These new allegations in the SAC fail to allege the existence of any contract between Walmart and Apple that benefitted Plaintiff.

Accordingly, Plaintiff has not alleged privity or any recognized privity exception adopted by the Ninth Circuit or California courts. Thus, the implied breach of warranty claim fails to state a claim and the Court GRANTS Defendants' motion to dismiss the breach of implied warranty of merchantability claim.

D. Leave to Amend

In opposition, Plaintiff seeks leave to amend in the event the Court dismisses any part of the SAC. (Dkt. No. 23 at 18.)

Where a motion to dismiss is granted, leave to amend should be granted "unless the court determines that the allegation of other facts consistent with the challenged pleading could not possibly cure the deficiency." DeSoto, 957 F.2d at 658 (quoting Schreiber Distrib. Co., 806 F.2d at 1401)). In other words, where leave to amend would be futile, the Court may deny leave to amend. See Desoto, 957 F.2d at 658 ; Schreiber, 806 F.2d at 1401. Here, because Plaintiff has failed to cure the deficiencies previously identified, the Court DENIES Plaintiff leave to amend.

Conclusion

Based on the reasoning above, the Court GRANTS Defendants' partial motion to dismiss the UCL claim, the equitable relief sought in the CLRA claim and the breach of implied warranty of merchantability claim without leave to amend.

IT IS SO ORDERED. Dated: May 3, 2021

/s/_________

Hon. Gonzalo P. Curiel

United States District Judge

pyrifos 4 (June 8, 2000), https://archive.epa.gov/scipoly/sap/meetings/web/pdf/hed_ra.pdf (discussing live animal studies and explaining that "new data in the literature also gave rise to uncertainties such as the suggestion that the inhibition of [AChE] may not be essential for adverse effects on brain development").

The EPA also began acting on its concerns about chlorpyrifos safety, in collaboration with the pesticide industry. In 2000, the EPA and the chlorpyrifos technical registrants entered into an agreement regarding chlorpyrifos that eliminated or phased out its use for virtually all residential and termiticide purposes, and on tomatoes and, during the growing season, grapes and apples. In 2002, the EPA announced certain risk mitigation measures, especially for people exposed to chlorpyrifos through their work.

Letter to Aaron Colangelo, NRDC, & Margaret Reeves, PANNA, from Steven Bradbury, EPA, re: Chlorpyrifos Petition Dated September 12, 2007 (hereinafter "2007 Petition"), at 6 (July 16, 2012).

Interim Reregistration Eligibility Decision for Chlorpyrifos, supra note 26.

Subject to these changes, however, the EPA determined in February 2002, based upon the evidence then available, that "[d]ietary exposures from eating food crops treated with chlorpyrifos are below the level of concern for the entire U.S. population, including infants and children," and that "[d]rinking water risk estimates . . . are generally not of concern." The EPA reiterated its safety finding in July 2006, stating that chlorpyrifos tolerances "meet the safety standard under Section 408(b)(2) of the FFDCA."

Id. at 2.

EPA, Office of Prevention, Pesticides and Toxic Substances, Memo to Jim Jones from Debra Edwards, Finalization of Interim Reregistration Eligibility Decisions and Interim Tolerance Reassessment and Risk Management Decisions for the Organophosphate Pesticides, and Completion of the Tolerance Reassessment and Reregistration Eligibility Process for the Organophosphate Pesticides 2 (July 31, 2006).

B. 2007: PANNA and NRDC File a Petition to Revoke Tolerances, Citing Mounting Evidence of Harm

In September 2007, PANNA and NRDC filed an administrative petition with the EPA seeking revocation of all chlorpyrifos tolerances under the FFDCA and the cancellation of all of chlorpyrifos's FIFRA registrations. The 2007 Petition asserted that scientific evidence now available showed that the current chlorpyrifos tolerances were not safe, especially for infants and children; indeed, they argued, "no safe level of early-life exposure to chlorpyrifos can be supported." They cited "[m]any studies published since 2001 [that] report that fetal exposure to chlorpyrifos is more damaging than adult exposure."

Marc S. Wu et al., NRDC, & Susan E. Kegley, PANNA, Petition to Revoke All Tolerances and Registrations for the Pesticide Chlorpyrifos 5 (Sept. 12, 2007).

Id. at 6.

The 2007 Petition relied in part upon certain experiments performed on live mice and rats. They were exposed in utero to levels of chlorpyrifos below those previously known to cause AChE inhibition. The scientists found marked declines in thinking and movement, indicative of neurological effects. The declines were sex-linked, harming males more than females.

The 2007 Petition also relied upon an epidemiological study, known as the "Columbia Study." Researchers worked with a cohort of pregnant women and their children, collecting data on the mothers' organophosphate exposure (including chlorpyrifos) during pregnancy, and then following the development of the children for many years. Some of the participating children were born before the EPA and the registrants agreed to end residential use of chlorpyrifos, and others were born after. Over time, the researchers found a correlation between prenatal chlorpyrifos exposure and several negative outcomes:

• at age three, lower performance in motor and mental development tests and higher incidences of attention-deficit hyperactivity disorder and autism spectrum disorder;
• at age seven, changes in brain morphology and lower IQ scores; and

• at age eleven, a greater likelihood of mild or moderate tremors.




Like the live animal experiments, the Columbia Study found that in utero exposures were harmful even beneath the levels thought to cause notable AChE inhibition and that harms were sex-linked, disproportionately affecting boys.

Two other groups of researchers also conducted epidemiological studies similar to the Columbia Study (the "Mount Sinai Study" and the "CHAMACOS Study"; collectively with the Columbia Study, the "Human Cohort Studies"). The Mount Sinai and CHAMACOS Studies looked at exposure to organophosphate pesticides and, like the Columbia Study, found a correlation between prenatal organophosphate exposure and cognitive impairments in early childhood.

Although the Mount Sinai Study and the CHAMACOS Study were not cited in the 2007 Petition, they later became part of the administrative record.

C. 2008-2011: The EPA Preliminarily Links Chlorpyrifos to Neurotoxic Harms in Infants and Children

Within a year of the 2007 Petition, the EPA, in August 2008, published a Science Issue Paper, which reviewed existing scientific studies and "preliminarily concluded that chlorpyrifos likely played a role" in the low birth rate and delays in infant mental development observed in the Human Cohort Studies. The EPA recognized that some of these studies found these effects despite lesser AChE inhibition, suggesting there was a different mechanism of harm. However, the paper also noted that it was "not a full and complete risk assessment/characterization," and that the EPA "ha[d] not developed any final conclusions regarding updates to the chlorpyrifos hazard assessment."

Health Effects Division, Office of Pesticide Programs, EPA, Science Issue Paper: Chlorpyrifos Hazard and Dose Response Characterization 52 (Aug. 21, 2008).

Id. at 40-41 & fig.5.

Id. at 7.

In September 2008, the EPA convened a committee of experts known as a Scientific Advisory Panel ("SAP") to peer-review its findings. The 2008 SAP considered "the results of the three [Human Cohort Studies] (with an emphasis on the Columbia [S]tudy) . . . along with the findings from experimental studies in animals," and concluded that "maternal chlorpyrifos exposure would likely be associated with adverse neurodevelopmental outcomes in humans." The SAP "agreed with [the EPA's] conclusion that chlorpyrifos likely played a role in the birth and neurodevelopmental outcomes noted in the three [Human Cohort Studies]."

SAP Minutes No. 2008-04, A Set of Scientific Issues Being Considered by the Environmental Protection Agency Regarding: The Agency's Evaluation of the Toxicity Profile of Chlorpyrifos 13 (Sept. 16-18, 2008) (hereinafter "2008 SAP Minutes").

Id. at 37.

However, the SAP also posited that the effects might not be entirely attributable to chlorpyrifos; rather, they might also reflect exposure to other AChE-inhibiting insecticides. A majority of SAP members agreed that the adverse outcomes of the Columbia Study were concerning, especially "in light of evidence demonstrating that low levels of exposure to toxicants once thought to have adverse neurodevelopmental effects only at high levels (i.e. lead, mercury, and PCBs) are now known to produce significant effects at lower levels." Nevertheless, the 2008 SAP found that the Human Cohort Studies had "utility for risk characterization, but not as the principal basis for establishing the point of departure."

Id. at 43-44.

2007 Petition, supra note 29, at 6-7. The Dissent notes that the 2008 SAP expressed "concerns that the Columbia Study—the most robust of the three—did not provide sufficient data to be the sole factor for risk assessment or modifying tolerances and produced uncertainty through its measurement method." Dissent, infra, at 91. In fact, although the 2008 SAP recognized that "there were limitations . . . that precluded [the Human Cohort Studies] from being used to directly derive the [point of departure] or the uncertainty factor," it also concluded that the Columbia Study "could be used to determine bounding values for the levels of chlorpyrifos that might cause a measurable effect." 2008 SAP Minutes, supra note 39, at 46. Thus, even as early as 2008, the SAP recognized the utility of the Columbia Study for risk assessment.

About three years later, in 2011, the EPA published a Preliminary Human Health Risk Assessment. The EPA discussed the three Human Cohort Studies and noted the 2008 SAP's conclusion that those studies, "in concert with the animal studies[,] indicate that 'maternal chlorpyrifos exposure would likely be associated with adverse neurodevelopmental outcomes in humans.'" While the Preliminary Human Health Risk Assessment asserted that the EPA could not yet identify the mechanism of action for neurotoxic harm, nevertheless, it viewed the Human Cohort Studies favorably, describing the Columbia Study as a "natural experiment" since some participants were pregnant before the EPA banned residential use of chlorpyrifos and some were pregnant after the ban. The EPA "intend[ed] to carefully consider the strengths and limitations of the epidemiology studies along with the available empirical data in a full weight of evidence analysis in the final [Human Health Risk Assessment]." Thus, while the EPA continued to use 10% AChE inhibition to set a point of departure, it explained that "ongoing analyses will ensure that [the points of departure] in [its] preliminary assessment are [also] human health protective for neurodevelopmental toxicity that may arise from pre- or postnatal exposure."

Memo from Danette Drew et al. to Tom Myers re: Chlorpyrifos: Preliminary Human Health Risk Assessment for Registration Review, EPA, at 28 (June 30, 2011).

Id. at 31.

Id. at 34.

Id. at 42.

D. 2012-2015: The EPA Expresses Increasing Certainty That Chlorpyrifos Causes Neurotoxic Effects in Infants and Children

In April 2012, having received no response from the EPA on the pertinent arguments raised in the 2007 Petition, PANNA and NRDC petitioned this Court for a writ of mandamus.

The 2007 Petition raised several other claims, some of which the EPA addressed at earlier points in time, but here petitioners only press the claims related to neurotoxic effects.

Meanwhile, also in April 2012, the EPA convened another SAP. The 2012 SAP opined with more certainty than the 2008 SAP that multiple "lines of evidence suggest that chlorpyrifos can affect neurodevelopment at levels lower than those associated with AChE inhibition, and that the use of AChE inhibition data may not be the most appropriate for . . . [assessing] the neurodevelopmental risks of chlorpyrifos." The 2012 SAP paid particular attention to the Human Cohort Studies and identified "nine strengths" of them, including, among others, the longitudinal design, the use of biomarkers of exposure (rather than only self-reported exposure), and "the relative consistency of findings in different populations while using similar standardized exposure and outcome measures." The 2012 SAP also identified some shortcomings of the Human Cohort Studies, such as a relatively small sample size and uncertainty regarding whether harms could be attributed to chlorpyrifos alone. Overall, though, it found that "[t]he strengths of the three studies support the Panel's conclusion."

SAP Minutes No. 2012-04, A Set of Scientific Issues Being Considered by the Environmental Protection Agency Regarding Chlorpyrifos Health Effects 53 (Apr. 10-12, 2012) (hereinafter "2012 SAP Minutes").

Id. at 18.

Id.

Specifically, the 2012 SAP, based on its review of all the evidence available at the time, "concur[red] with the 2008 SAP and the Agency in concluding that chlorpyrifos likely plays a role in impacting the neurodevelopmental outcomes examined in the three cohort studies." It noted that the Human Cohort Studies showed potentially serious harms to infants and children, including "abnormal reflexes in the newborn, pervasive development disorder at 24 or 36 months, mental development at 7-9 years, and attention and behavior problems at 3 and 5 years of age."

Id.

Id. at 17.

Despite all this, the EPA, following issuance of the 2012 SAP report, still did not take final action on the 2007 Petition; but it represented in the mandamus proceedings that it had "a concrete timeline for final agency action that would resolve the 2007 Petition by February 2014." In light of that representation, this Court, in July 2013, denied PANNA and NRDC's petition for a writ of mandamus.

PANNA v. EPA (In re PANNA), 532 F. App'x 649, 651 (9th Cir. 2013).

February 2014 came and went, but the EPA did not take final action on the 2007 Petition. PANNA and NRDC returned to this Court in September 2014 with a second petition for a writ of mandamus.

Shortly thereafter, in December 2014, the EPA published a Revised Human Health Risk Assessment. It expressed greater certainty both that chlorpyrifos was causing the neurotoxic harms seen in the cohort studies and that it was doing so through a mechanism other than AChE inhibition.

Memo from Danette Drew et al. to Tom Myers et al. re: Chlorpyrifos: Revised Human Health Risk Assessment for Registration Review, EPA (Dec. 29, 2014) (hereinafter "2014 Revised Human Health Risk Assessment"), at 43 ("[C]hlorpyrifos likely played a role in the neurodevelopmental outcomes observed in these epidemiology studies."); id. at 46 ("[The] EPA believes it is unlikely mothers enrolled in the [Human Cohort Studies] experienced [red blood cell] AChE inhibition"); see also id. ("Given the differences across laboratory animal and epidemiology studies, the qualitative similarity in research findings is striking.").

Because the EPA concluded that chlorpyrifos could cause harm even if exposure was below the AChE inhibition-related point of departure, the EPA proposed a new method for calculating a point of departure. But with all this, the EPA still did not act on the 2007 Petition.

In August 2015, this Court therefore granted the second mandamus petition. The EPA had offered an "ambiguous plan to possibly issue a proposed rule nearly nine years after receiving the administrative petition," and the Court found this to be "too little, too late." The Court found the EPA's delay "egregious" and ordered the EPA "to issue a full and final response to the petition no later than October 31, 2015."

PANNA v. EPA (In re PANNA), 798 F.3d 809, 811 (9th Cir. 2015).

Id.

Id.

E. 2015-2016: The EPA Finds That Chlorpyrifos Tolerances Are Unsafe

Once again, this Court's deadline came and went, and the EPA still did not take final action on the 2007 Petition. But in November 2015, the EPA published in the Federal Register a Notice of Proposed Rulemaking "proposing to revoke all tolerances for residues of the insecticide chlorpyrifos." It wrote: "The agency is proposing to revoke all of these tolerances because [the] EPA cannot, at this time, determine that aggregate exposure to residues of chlorpyrifos, including all anticipated dietary exposures and all other non-occupational exposures for which there is reliable information, are safe." Specifically, the EPA found that "contributions to dietary exposures to chlorpyrifos from food and residential exposures are safe," but "when those exposures are combined with estimated exposures from drinking water, as required by the FFDCA, . . . safe levels of chlorpyrifos in the diet may be exceeded for people whose drinking water is derived from certain vulnerable watersheds throughout the United States."

Chlorpyrifos; Tolerance Revocations, 80 Fed. Reg. 69,080, 69,081 (Nov. 6, 2015) (hereinafter "2015 Notice of Proposed Rulemaking").

Id.

Id.

The EPA adhered to the findings of the 2014 Revised Human Health Risk Assessment. It relied upon "a considerable and still-growing body of literature on the effects of chlorpyrifos on the developing brain of laboratory animals (rats and mice) indicating that gestational and/or postnatal exposure may cause persistent behavioral effects into adulthood." It also relied upon the three Human Cohort Studies:

Id. at 69,090.

[The] EPA has considered the strengths and limitations of these studies, and believes that random or systematic errors in the design, conduct or analysis of these studies were unlikely to fully explain observed positive associations between in utero [organophosphate] exposure and adverse neurodevelopmental effects observed at birth and through childhood (age 7 years). [The] EPA believes these are strong studies which support a conclusion that [organophosphates] likely played a role in these outcomes.

The EPA acknowledged "significant uncertainties . . . about the actual exposure levels experienced by mothers and infant participants in the three children's health cohorts," but found that the measured exposures "are likely low enough that they were unlikely to have resulted in AChE inhibition."

Id. at 69,091.

Id. at 69,093.

Since, however, the proposed rule did not constitute a final response to the 2007 Petition, this Court, in December 2015, ordered the EPA "to take final action by December 30, 2016 on its proposed revocation rule and its final response to . . . [the] 2007 [P]etition." In other words, this Court, despite the EPA's repeated disregard of this Court's orders, most leniently gave the EPA yet another year to rule on the 2007 Petition.

PANNA v. EPA (In re PANNA), 808 F.3d 402 (9th Cir. 2015).

In April 2016, the EPA convened another SAP, which peer-reviewed the 2014 Revised Human Health Risk Assessment. The 2016 SAP "agree[d] that both epidemiology and toxicology studies suggest there is evidence for adverse health outcomes associated with

Use AI to get other relevant cases.

Comments

Shay v. Apple Inc.
(May 3, 2021)